Clinical Trials Logo

Hematologic Malignancy clinical trials

View clinical trials related to Hematologic Malignancy.

Filter by:

NCT ID: NCT04136275 Completed - Lymphoma Clinical Trials

CAR-37 T Cells In Hematologic Malignancies

Start date: June 19, 2020
Phase: Phase 1
Study type: Interventional

This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells. - Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) is an investigational treatment

NCT ID: NCT03992352 Completed - Clinical trials for Hematologic Malignancy

Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)

BMT CTN 1704
Start date: July 19, 2019
Phase:
Study type: Observational

Prospective observational multicenter study of allogeneic Hematopoietic Stem Cell Transplantation (HCT) in recipients 60 years and older to assess important determinants of health status to be combined into a composite health risk model to improve risk assessment of non-relapse mortality (NRM).

NCT ID: NCT03903185 Completed - Clinical trials for Hepatitis C, Chronic

Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

Start date: March 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at studying the PK of ledipasvir, sofosbuvir, and GS-331007 metabolite in HCV infected children with hematological malignancy. In this study, patients in both treatment groups will receive 12 weeks of treatment with a fixed-dose combination tablet containing 45 mg of ledipasvir and 200 mg of sofosbuvir (LDV/SOF) orally, once daily with food.

NCT ID: NCT03800758 Completed - Clinical trials for Hematologic Malignancy

Expressive Helping for Stem Cell Transplant Patients

Start date: March 6, 2019
Phase: Phase 3
Study type: Interventional

The Writing for Insight, Strength, and Ease (WISE) Study is a multisite Randomized Controlled Trial (RCT) testing the efficacy of the Expressive Helping (EH) intervention among adults receiving hematopoietic stem cell transplantation.

NCT ID: NCT03699631 Completed - Clinical trials for Hematologic Malignancy

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

Start date: November 6, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II open-label trial designed to evaluate the efficacy of tocilizumab in improving GVHD-free/relapse-free survival (GRFS) after allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.

NCT ID: NCT03654404 Completed - Clinical trials for Hematologic Malignancy

A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients

Start date: September 11, 2018
Phase: N/A
Study type: Interventional

The goal of this research study is to find out if a novel phone-based positive psychology intervention that focuses on improving health behaviors and positive emotions can help improve mood, health related quality of life, and overall function in patients who have just undergone hematopoietic stem cell transplantation as part of blood cancer treatment.

NCT ID: NCT03555955 Completed - Clinical trials for Acute Myeloid Leukemia

A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

Start date: November 20, 2018
Phase: Phase 1
Study type: Interventional

This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.

NCT ID: NCT03419078 Completed - Clinical trials for Graft Versus Host Disease

Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)

Start date: December 2015
Phase:
Study type: Observational

Retrospective case-note review to determine if nutrition via the enteral compared to the parenteral route results in better outcomes after haematopoietic cell transplantation.

NCT ID: NCT03399149 Completed - Clinical trials for Respiratory Insufficiency

Systematic Evaluation by an Intensivist of Hematological Malignancy Patients Presenting With Acute Respiratory or Hemodynamic Failure

CAREHEMA
Start date: February 13, 2017
Phase:
Study type: Observational

Over the last two decades, the number of patients with hematological malignancies (HMs) admitted to the ICU increased and their mortality has dropped sharply. Patients with HMs increasingly require admission to the intensive care unit (ICU) for life-threatening events related to the malignancy and/or treatments, with immunosuppression being a major contributor. Whether the increase in ICU admissions is related to increased referrals by hematologists and/or to increased admissions by intensivists is unknown. The criteria used for ICU referral and admission decisions have not been extensively evaluated. Finally, the links between admission policies and treatment-limitation decisions are unclear, but ICUs with broad admission policies may change the treatment goals based on the response to several days of full-code management. The aim of this study is to evaluate the impact of a systematic evaluation by an intensivist of HMs patients presenting with acute respiratory and/or hemodynamic failure.

NCT ID: NCT03149055 Completed - Clinical trials for Hematologic Malignancy

Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Start date: May 4, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to study the effects of isavuconazole in preventing fungal infections in patients who have had a hematopoietic stem cell transplant (HCT).